U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshot: CIBINQO
  1. Drug Approvals and Databases

Drug Trials Snapshot: CIBINQO

The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.

Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable). Refer to the CIBINQO Prescribing Information for all of the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).

CIBINQO (abrocitinib)
(sih-BIN’ koe)
Pfizer, Inc.
Original Approval date: January 14, 2022


What is the drug for?

CIBINQO is a Janus Kinase (JAK) inhibitor that is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

How is this drug used?

CIBINQO is an oral tablet that is taken once daily. Take 100 mg once daily to start, if an adequate response is not achieved with CIBINQO 100 mg daily after 12 weeks, consider increasing dosage to 200 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 200 mg once daily.

Who participated in the clinical trials?

The FDA approved CIBINQO based on evidence from 3 controlled clinical trials enrolling a total of 1615 patients supporting efficacy and safety. Two of the trials enrolled patients 12-years of age and older with moderate-to-severe atopic dermatitis and one trial enrolled adults with moderate-to-severe atopic dermatitis. The trials were conducted at multiple sites in 18 countries (i.e., United States, Canada, Australia, Mexico, Chile, Great Britain, Poland, Germany, Bulgaria, Hungary, Czech Republic, Latvia, Slovakia, Spain, Italy, Japan, Korea, Taiwan).

In addition, safety analyses were performed on the combined results of these 3 controlled clinical trials and one additional controlled study in a total of 1,540 patients.

What are the benefits of this drug?

More patients achieved clear or almost clear skin and a reduction in itch after treatment with CIBINQO in comparison to those who were treated with placebo.

Were there any differences in how well the drug worked in clinical trials among sex, race and age?

  • Sex: CIBINQO worked slightly better in females than males; however, this was not consistent across CIBINQO doses, endpoint and trials.
  • Race: CIBINQO worked similarly in White and Asian patients. The number of patients of races other than White and Asian was limited; therefore, differences in response among races could not be determined.
  • Age: CIBINQO worked similarly in those <18 years of age and those 18-64 years of age. The number of patients above 65 years of age was limited; therefore, differences in response between patients above and below 65 years of age could not be determined.

What are the possible side effects?

The most common side effects of CIBINQO in clinical trials were nasopharyngitis, nausea, headaches, herpes simplex (including oral herpes, ophthalmic herpes, herpes dermatitis and genital herpes), and increase in blood creatine phosphokinase.

CIBINQO can cause serious infections, malignancy, major cardiac events, thrombosis and other laboratory abnormalities including thrombocytopenia, lymphopenia, and lipid elevations.

Patients should not receive live vaccines while being treated with CIBINQO.

Were there any differences in side effects of the clinical trials among sex, race, and age?

  • Sex: The occurrence of side effects was similar in males and females
  • Race: The occurrence of side effects was similar in White, Asian, Black or African American patients.
  • Age: The number of patients above 65 years of age was limited; therefore, differences in adverse event rates between patients above and below 65 years of age could not be determined.


Figure 1 summarizes how many males and females were enrolled in the combined clinical trials used to evaluate the efficacy of CIBINQO.

Figure 1. Baseline Demographics by Sex (Full Analysis Set)

Pie chart summarizing how many individuals of certain sex were enrolled in the clinical trial. In total, 757 patients were female (47%) and 858 patients were male (53%).

Adapted from FDA Review

Figure 2 summarizes the percentage of patients by race enrolled in the combined clinical trials used to evaluate the efficacy of CIBINQO.

Figure 2. Baseline Demographics by Race (Full Analysis Set)

Pie chart summarizing how many individuals of a certain race were enrolled in the clinical trial. In total, 1117 patients were White (79%), 88 patients were Black or African American (6%), 189 patients were Asian or Pacific Islander (13%) and 31 patients were Other (2%).

* Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander and multiple races.

Adapted from FDA Review

Figure 3 summarizes how many patients by race were in the combined trials used to evaluate the side effects of CIBINQO.

Figure 3. Baseline Demographics by Age (Full Analysis Set)

Pie chart summarizing how many individuals of certain age groups were enrolled in the clinical trial. In total, 124 patients were between the ages for 12 and 18 (8%), 1402 patients were between the ages of 18 to 65 years old (87%), and 89 patients were 65 years and older (5%).

Adapted from FDA Review

How were the trials designed?

The benefit and side effects of CIBINQO were evaluated in three clinical trials of 12 year and older patients with moderate-to-severe atopic dermatitis not adequately controlled by topical medications(s). Trial-AD-1 and Trial-AD-2 were monotherapy trials in adolescents and adults, while Trial-AD-3 was a trial with background topical therapy in adults only.

All three trials evaluated two doses of CIBINQO: 100mg and 200mg. The monotherapy trials were identically designed, 16-week, randomized, multicenter, double-blind, placebo-controlled, parallel group, phase 3 trials. Trial-AD-3 with concomitant background therapy was a 24-week, multicenter, randomized, double-blind, active-comparator (dupilumab) and placebo-controlled, phase 3 trial. In this trial, at Week 16, subjects previously receiving placebo were re-randomized to receive CIBINQO 100 mg or 200 mg, subjects previously receiving CIBINQO continued on their respective dose and subjects previously receiving dupilumab continued to take placebo.

The benefit of CIBINQO to placebo was assessed after 12 weeks of treatment using the Investigator Global Assessment (IGA) scale that measures the severity of disease on a scale from 0 to 4 and the Eczema Area and Severity Index (EASI) for all three trials.


CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.
COMPARATOR: A previously available treatment or placebo that is compared to the actual drug being tested.
EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.
PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.


Back to Drug Trials Snapshots

Back to Top